We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Exenatide (GLP-1 receptor agonist)
The first-in-class GLP-1 receptor agonist — an FDA-approved prescription drug for type 2 diabetes (Byetta twice-daily, Bydureon once-weekly). Honest appraisal: it genuinely lowers HbA1c and produces modest weight loss in solid phase-3 RCTs (the DURATION program), but its dedicated cardiovascular-outcomes trial, EXSCEL, was NEUTRAL on its primary endpoint (HR 0.91, P=0.06 for superiority). It is older and less potent than newer agents (liraglutide beat it head-to-head; semaglutide and tirzepatide are stronger still), and it is increasingly superseded in practice. It is a prescription medicine, not a supplement, and not auto-recommended.
Prescription medication — not a dietary supplement
Exenatide is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Exenatide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2004–2026 with a typical study size of 377 participants.
Based on 113 studies · 24 meta-analyses · 78 RCTs · 18,216 total participants
Confidence
High confidenceBy outcome
An FDA-approved GLP-1 drug with solid phase-3 RCTs showing real HbA1c and modest weight reduction, but its cardiovascular-outcomes trial was neutral and it is less potent than newer agents — hence Moderate, not high.
76 randomised trials
92% were about Exenatide in an audit of 50 of them
Every randomised or controlled trial of Exenatide indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
21 trials ongoing or recruiting · 274 completed on ClinicalTrials.gov
112 of the completed trials have posted results
Registered trials show research momentum for Exenatide, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Exenatide is a synthetic version of exendin-4, a peptide from the Gila monster's saliva that mimics the human incretin hormone GLP-1 (glucagon-like peptide-1). It was the first GLP-1 receptor agonist brought to market (Byetta, approved 2005), later joined by an extended-release once-weekly formulation (Bydureon).
The EU marketing authorisations for Byetta and Bydureon were withdrawn on 1 January 2026 at the company’s request for commercial reasons. It is a prescription drug, NOT a dietary supplement, approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.
Mechanistically it activates the GLP-1 receptor in the pancreas (glucose-dependent insulin secretion, suppressed glucagon), the brain (appetite suppression/satiety), and the gut (slowed gastric emptying). The efficacy evidence is solid but moderate by modern standards.
The pivotal AMIGO trials showed twice-daily exenatide added to metformin or a sulfonylurea reduced HbA1c by ~0.8% with dose-dependent weight loss (DeFronzo 2005; Buse 2004).
The DURATION program then established the once-weekly formulation: DURATION-1 showed once-weekly beat twice-daily on HbA1c (-1.9% vs -1.5%); DURATION-3 maintained an HbA1c edge over insulin glargine at 3 years with weight loss instead of weight gain; DURATION-2 beat sitagliptin and pioglitazone.
The honest counterweight is potency and outcomes. Head-to-head, liraglutide lowered HbA1c more than exenatide twice-daily (LEAD-6) and matched once-weekly exenatide while being better tolerated (DURATION-6, where exenatide did NOT meet non-inferiority vs liraglutide).
Most importantly, the dedicated cardiovascular-outcomes trial EXSCEL (14,752 patients) was NEUTRAL: the primary MACE composite was non-inferior for safety but NOT superior for efficacy (HR 0.91; 95% CI 0.83-1.00; P=0.06 for superiority) — in contrast to liraglutide (LEADER), semaglutide (SUSTAIN-6/SELECT), and dulaglutide (REWIND), which all showed significant cardiovascular benefit.
Newer GLP-1 agents are more potent on glycemia and weight, simpler to dose, and carry proven cardiovascular benefit, so exenatide is increasingly a legacy option.
Safety mirrors the class: in the US, extended-release exenatide (Bydureon BCise) carries a US FDA boxed warning for thyroid C-cell tumors, which immediate-release Byetta does not, plus risks of pancreatitis and gallbladder disease, very common GI side effects, dose adjustment/avoidance in renal impairment, and injection-site reactions (more with the once-weekly depot).
It should be used only under a clinician's care for a genuine medical indication, and compounded/grey-market exenatide should be avoided.
A synthetic exendin-4 peptide (the first-in-class GLP-1 receptor agonist) that binds and activates the GLP-1 receptor in the pancreas, brain, and gastrointestinal tract — the upstream target driving all downstream effects.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon, lowering blood glucose and HbA1c with low intrinsic hypoglycemia risk.
Acts on central appetite-regulating circuits to increase satiety and reduce food intake, contributing to the modest weight loss seen across the AMIGO and DURATION trials.
Delays gastric emptying — blunting post-meal glucose excursions (especially with twice-daily dosing) and prolonging fullness — and the mechanism behind much of the nausea.
How Exenatide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Contraindicated for extended-release exenatide (Bydureon BCise) under the US label, which carries a US FDA boxed warning for thyroid C-cell tumors. Immediate-release Byetta does not carry this US boxed warning. The EU marketing authorisations for Byetta and Bydureon were withdrawn on 1 January 2026 at the company’s request for commercial reasons. In Germany or Austria, discuss current availability and authorised alternatives with your prescriber. Do not stop or change your prescribed diabetes treatment on your own.
Use with caution; avoid in severe impairment (eGFR <30) and end-stage renal disease — exenatide is renally cleared and there are reports of acute kidney injury.
Use with caution under specialist guidance; generally avoid with prior pancreatitis.
Contraindicated — not recommended in pregnancy or breastfeeding.
Not appropriate — exenatide is not approved for weight management, and newer agents have far stronger weight-loss evidence. This is a prescription drug with real risks, not a cosmetic shortcut.
Combining with a sulfonylurea or insulin raises hypoglycemia risk; the clinician typically reduces those agents. Exenatide alone is low-hypoglycemia (glucose-dependent action).
Delayed gastric emptying can slow/reduce absorption of co-administered oral drugs; take time-sensitive oral medicines (antibiotics, oral contraceptives) at least 1 hour before twice-daily exenatide.
Post-marketing reports of increased INR, sometimes with bleeding, when exenatide is added — monitor INR more closely.
Do not combine with another GLP-1 agonist (e.g. liraglutide, dulaglutide, semaglutide, tirzepatide) — additive risk with no added benefit.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Rotate injection sites; usually resolves; report persistent or painful nodules
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment. Reduce sulfonylurea/insulin dose under clinician guidance. Carry fast-acting carbohydrate.
Tip: Seek care for upper-right abdominal pain, fever, or jaundice
Tip: Discontinue and seek urgent care for severe, persistent abdominal pain radiating to the back
Tip: More likely with dehydration from GI losses; maintain hydration, monitor renal function, avoid in severe renal impairment
Exenatide has an evidence score of 6/10 — moderate evidence based on 113 indexed studies, including 3 meta-analyses. The first-in-class GLP-1 receptor agonist — an FDA-approved prescription drug for type 2 diabetes (Byetta twice-daily, Bydureon once-weekly). Honest appraisal: it genuinely lowers HbA1c and produces modest weight loss in solid phase-3 RCTs (the DURATION program), but its dedicated cardiovascular-outcomes trial, EXSCEL, was NEUTRAL on its primary endpoint (HR 0.91, P=0.06 for superiority). It is older and less potent than newer agents (liraglutide beat it head-to-head; semaglutide and tirzepatide are stronger still), and it is increasingly superseded in practice. It is a prescription medicine, not a supplement, and not auto-recommended. Representative study: PMID 24263424.
Dosing for Exenatide: Prescription-only, clinician-directed. Subcutaneous. Byetta (twice-daily): 5 µg before two main meals, escalated to 10 µg after ~1 month. Bydureon (once-weekly extended-release): 2 mg subcutaneously once weekly. DO NOT self-dose. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Exenatide — consistent daily use matters more than the time of day. Twice-daily exenatide (Byetta) is injected within 60 minutes BEFORE the two main meals (not after); the once-weekly form (Bydureon) is injected on the same day each week regardless of meals.
Exenatide should be used with caution — talk to a healthcare provider before taking it. Reported side effects include acute pancreatitis, acute kidney injury / worsening renal function, hypoglycemia (with sulfonylurea or insulin). How often they occur is not established for all of them. Use caution if any of these apply to you: Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label for extended-release exenatide, Bydureon BCise, not for immediate-release Byetta); Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label for extended-release exenatide, Bydureon BCise, not for immediate-release Byetta); Severe renal impairment (eGFR <30 mL/min) or end-stage renal disease — exenatide is renally cleared.
Semaglutide
Too few graded studiesAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Too few graded studiesAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Orforglipron
Too few graded studiesAn ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity, also studied in type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. In the US, orforglipron is approved as Foundayo for long-term weight management in adults with obesity, or overweight with at least one weight-related condition, together with a reduced-calorie diet and increased physical activity. FDA approval was granted on 1 April 2026. An EMA list dated 5 October 2026 places orforglipron under evaluation. Honest appraisal: the phase-2 data are strong and the phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), the US label carries a boxed warning about thyroid C-cell tumours, and long-term outcomes are unsettled. It is NOT a dietary supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 113 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research